This is a randomized, multicenter, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HW091077 in Chinese adult subjects with refractory chronic cough or unexplained chronic cough (RCC/UCC).
Aged between 18 and 80 years;
Diagnosed with refractory chronic cough or unexplained chronic cough, with a cough lasting for ≥1 year;
Chest CT at screening shows no abnormalities that the investigator believes may lead to chronic cough;
Cough severity VAS score ≥40 mm ;
Currently smoking, or having quit smoking within 12 months prior to screening;
A smoking history of >20 pack-years;
Ongoing exposure to inhaled toxic substances within 12 months prior to screening or currently;
A history of drug abuse or alcoholism (weekly alcohol consumption of 14 units of alcohol: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);